Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Berkley Renewables Inc.

Market Cap 364K 318K 294K 275K 517K 34.38M 520K 3.49M 1.35M 16.92M 1.37M 1.34M 58.77M P/E 2016
4.22x
P/E 2017 -1.16x
Enterprise Value 5.13M 4.47M 4.14M 3.87M 7.27M 484M 7.31M 49.1M 19.03M 238M 19.24M 18.83M 827M EV / Sales 2016
3.53x
EV / Sales 2017 3.18x
Free-Float
90.7%
Yield 2016 *
-
Yield 2017 -
10 years 0.02
Extreme 0.015
0.15
Manager TitleAgeSince
Chief Executive Officer 63 2002-06-19
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 63 -
Director/Board Member 66 2006-08-16
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-.--% 459K
-3.12%-7.90%+13.78%+3.90% 131B
+1.23%-7.48%+27.52%+62.99% 86.08B
-2.45%-4.88%+3.72%+17.24% 69.23B
-1.07%-4.49%+23.28%+43.73% 51.62B
-2.30%-8.35%+13.57%-9.83% 51.54B
-1.08%-7.04%+22.83%-13.94% 48.58B
+0.37%-9.65%+77.41%+60.99% 47.07B
-0.90%-2.34%+11.30%-18.61% 38.69B
+7.21%+6.09%+52.50%+39.59% 36.46B
Average -0.21%-4.59%+24.59%+18.61% 56.05B
Weighted average by Cap. -0.81%-5.67%+23.98%+21.04%

Financials

2016 2017
Net sales 1.03M 902K 835K 782K 1.47M 97.57M 1.47M 9.91M 3.84M 48.03M 3.88M 3.8M 167M 1.72M 1.5M 1.39M 1.3M 2.45M 163M 2.46M 16.52M 6.4M 80.11M 6.47M 6.34M 278M
Net income 173K 151K 139K 131K 245K 16.3M 246K 1.65M 641K 8.02M 648K 634K 27.85M -631K -550K -509K -477K -894K -59.49M -899K -6.04M -2.34M -29.28M -2.37M -2.32M -102M
Net Debt 2.92M 2.54M 2.36M 2.21M 4.14M 275M 4.16M 27.94M 10.83M 135M 10.95M 10.71M 470M 4.76M 4.15M 3.84M 3.6M 6.75M 449M 6.79M 45.61M 17.68M 221M 17.87M 17.49M 768M
Logo Berkley Renewables Inc.
Berkley Renewables Inc. is a Canada-based, growth-oriented diversified issuer also pursuing renewable energy opportunities, primarily in the solar energy sector. The Company is pursuing solar energy investments in Ontario, Canada. It is also engaged in developing autologous cell therapies to treat conditions linked to a deficit of healthy cells required for normal healing and function through RepliCel Life Sciences Inc. The Company's RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aged skin and pattern baldness. The Company is also developing a proprietary injection device (RCI) for optimal clinical delivery. The Company is developing solar photovoltaic (PV) projects in Ontario, Canada, through its subsidiary, Solar Flow-Through General Partnership. Working with Solar Flow-Through, the Company has also developed a flow-through investment vehicle for investors to participate in Ontario's solar energy growth.
Employees
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!